Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II

Stephanie Ghazal 1†, Zainab Ridha 2†, Kathleen D’Aguanno 1, David Nassim 1, Andrea Quaiattini 3, Elena Netchiporouk 4,5, Yves Poulin 6, Sunil Kalia 7, Danielle Marcoux 8, Vincent Piguet 5,10 and Carolyn Jack 1,4,5,11,12

1 Faculty of Medicine, McGill University, Montreal, QC, Canada, 2 Faculty of Medicine, Université Laval, Quebec City, QC, Canada, 3 Schulich Library of Physical Sciences, Life Sciences, and Engineering, McGill University, Montreal, QC, Canada, 4 Division of Dermatology, McGill University Health Center, Montreal, QC, Canada, 5 Infectious Diseases and Immunology in Global Health, The Research Institute of the McGill University Health Center, Montreal, QC, Canada, 6 Centre de Recherche Dermatologique du Québec Métropolitain, Quebec City, QC, Canada, 7 Department of Dermatology and Skin Science, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada, 8 Department of Pediatrics, Division of Dermatology, Sainte-Justine University Hospital Center, University of Montreal, Montreal, QC, Canada, 9 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, 10 Division of Dermatology, Women’s College Hospital, Toronto, ON, Canada, 11 Divisions of Dermatology, St. Mary’s Hospital, Montreal West Island Integrated University Health and Social Services Centre, Montreal, QC, Canada, 12 Jewish General Hospital, Montreal West-Central Integrated University Health and Social Services Centre, Montreal, QC, Canada

Introduction: Since its approval for adults with moderate-to-severe atopic dermatitis (AD) in 2017, dupilumab has been incorporated into clinical practice guidelines (CPGs). However, recommendations differ internationally, and the quality assessment of their development is unclear.

Objective: We aimed to systematically review and appraise the quality of CPGs for adult AD reported since 2017 and map the recommendations for dupilumab initiation relative to conventional systemic therapy (CST).

Materials and Methods: A literature search was conducted in June 2020 in MEDLINE, EMBASE, SCOPUS, and CINAHL. Twelve CPGs were retrieved. Methodological quality was assessed using the validated Appraisal of Guidelines for Research & Evaluation II tool (AGREE-II). Recommendations were extracted and compared.

Results: AGREE-II median scores per domain of the CPGs were (%), $r =$ range): scope/purpose, 78% (50–96); stakeholder involvement, 54% (28–85); rigor of development, 39% (21–63); clarity of presentation, 85% (69–100); applicability, 27% (6–51); and editorial independence, 76% (42–100). Neither met the threshold of 70% quality criteria for rigor of development nor the applicability domains. Three CPGs met the criteria for recommendation without modification. CPGs’ approach to dupilumab initiation was as follows: second line, preferred over CST and nbUVB ($n = 1/12$ CPG); second line, equivalent to CST or nbUVB ($n = 3/12$ CPGs); third line, after nbUVB or CST ($n = 5/12$ CPGs); and fourth line after nbUVB and CST ($n = 2/12$). No consensus was reached for $n = 1/12$ CPG.
**INTRODUCTION**

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease worldwide, affecting up to 20% of children (1–5). Prevalence rates in adults can be as high as 10% (6, 7). AD management is typically based on a short-term reactive treatment of acute flares and long-term maintenance therapy (8, 9). In severe or refractory cases, systemic therapy is often warranted (10, 11). While systemic corticosteroids have long been approved by the Food and Drug Administration (FDA), their use, especially long-term, is discouraged due to the breadth of cumulative adverse effects (12). Traditional antimetabolite immuno-modulators, such as azathioprine, mycophenolate mofetil, cyclosporine, and methotrexate, are often used off-label to control severe diseases (8, 9, 13, 14). Dupilumab is the first therapy to be approved for moderate-to-severe AD that does not respond to topical therapies based on large, randomized, double-blind placebo-controlled clinical trials (10, 15–28). More approvals for novel systemic targeted therapies for AD are anticipated in the next few years, including biologics and small molecules such as Janus kinase (JAK) inhibitors (29). Since access to targeted therapies may be restricted by cost, clear guidelines specifying the sequence of available immunomodulating agents in treatment algorithms remain an outstanding need.

The most widely adopted guidelines for AD management were published by the American Academy of Dermatology in 2014; however, these predate the approval of dupilumab, leaving a gap of evidence-based, practical recommendations for up-to-date management of adult AD (8, 9). A number of recent clinical practice guidelines (CPGs) and recommendations from various groups were developed internationally to incorporate dupilumab in treatment algorithms (30–42). To the best of our knowledge, the quality of these CPGs’ methods and development processes have not yet been assessed. Furthermore, recommendations vary across CPGs, particularly with regard to indications on how to initiate, sequence, or combine systemic therapies.

To address this gap, we conducted this systematic review of CPGs for adult AD published since the approval of dupilumab in 2017. We aimed to assess the quality of methods and rigor of development processes of CPGs and map their recommendations regarding the position of dupilumab in their treatment algorithms.

**Conclusion and Relevance:** Dupilumab is now incorporated into CPGs for adult AD. These CPGs exhibited good quality in scope/purpose, clarity, and editorial independence domains. However, none met AGREE-II criteria for methodological rigor/applicability. Gaps were found in mechanisms for updates, facilitators/barriers, resource implications, and stakeholder involvement. Only \( n = 3 \) of 12 CPGs met quality criteria for recommendation without modifications. Of these, two favored a conservative sequential approach for the initiation of dupilumab relative to CST, while one did not reach consensus. Our findings highlight divergent recommendations AD treatment, underlining a need to incorporate quality criteria into future guideline development.

**Keywords:** dupilumab, treatment guideline, atopic dermatitis, systematic review, quality appraisal, AGREE-II

---

**MATERIALS AND METHODS**

**Database**

A systematic literature search was conducted on June 3, 2020 in MEDLINE, EMBASE, SCOPUS, and CINAHL. The search was limited to English articles published after 2017 since dupilumab received FDA approval in March 2017, European Medicines Agency (EMA) approval in September 2017, and Health Canada approval in November 2017 (43–46).

**Search Terms**

The search terms were decided on via consultation with AD experts, as well as methodologists with expertise in systematic reviews and quality appraisals. The following search terms were chosen: “atopic dermatitis” or “eczema” and “dupilumab” or “Dupixent” or “regn 668” or “sarat 231893.” The rationale for choosing these terms was based on the reasoning that up-to-date guidelines for AD management in adults should include dupilumab in their treatment algorithm as the first biologic option with AD disease-specific regulatory approval for efficacy and safety.

**Article Selection**

Results from MEDLINE, EMBASE, SCOPUS, and CINAHL were combined and exported to Endnote, where duplicates were removed. Two reviewers (SG & ZR) independently screened the articles containing recommendations for dupilumab initiation in the management of AD by title and abstract when available on the Rayyan software using predetermined exclusion and inclusion criteria (Figure 1) (47).

**Exclusion Criteria**

Articles were excluded if they met one or more of the following exclusion criteria:

- Not specific to management of AD.
- Not focused on the adult population.
- Case reports, case series, summaries, or abstracts.

**Inclusion Criteria**

The remaining articles were screened based on full content and were included only if they met both of the following inclusion criteria:
- Included treatment recommendations, consensus guidelines, position statements, or treatment algorithms for adults with moderate-to-severe AD.
- Included dupilumab in their treatment recommendations or algorithm.

Discrepancies between the two reviewers were resolved by discussion. If an agreement was not reached, a third reviewer (CJ) resolved the discrepancies.

**Article Characteristics**

Two independent reviewers (SG and ZR) extracted the following information for each article included for review: authors, publication date, country of development, patient category described, scoring tool used to assess AD severity, and the method used to reach a consensus based on recommendations.

**Assessment of Guidelines Quality**

The quality of CPGs was independently assessed by three reviewers (ZR, KD, and DN) using the validated Appraisal of Guidelines for Research and Evaluation II (AGREE-II) instrument. AGREE-II is an online tool used to evaluate the quality of methods and rigor of development of published CPGs (48–50). It is comprised of 23 items organized into six domains: scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, and editorial independence (Table 1). Each item is scored on a 7-point scale from 1 (strongly disagree) to 7 (strongly agree). All reviewers completed the AGREE-II training and practice exercise before starting the appraisal.

After the reviewers independently scored each CPG, scores were revealed and the domain percentages were calculated following the AGREE-II methodology as follows: (obtained...
TABLE 1 | Presentation of the 23 criteria evaluated in each of the six AGREE-II quality instrument domains.

| AGREE-II domain                  | Criteria evaluated                                                                 |
|----------------------------------|--------------------------------------------------------------------------------------|
| 1. Scope and purpose             | • The overall objectives of the guideline are specifically described                |
|                                  | • The health questions covered by the guideline are specifically described         |
|                                  | • The population to whom the guideline is meant to apply is specifically described   |
| 2. Stakeholder involvement       | • The guideline development group includes individuals from all relevant professional groups |
|                                  | • The views and preferences of the target population have been sought               |
|                                  | • The target users of the guideline are clearly defined                              |
| 3. Rigor of development          | • Systematic methods were used to search for evidence                               |
|                                  | • The criteria for selecting the evidence are clearly described                     |
|                                  | • The strengths and limitations of the body of evidence are clearly described       |
|                                  | • The methods for formulating the recommendations are clearly described             |
|                                  | • The health benefits, side effects and risks have been considered in formulating the recommendations |
|                                  | • There is an explicit link between the recommendations and the supporting evidence |
|                                  | • The guideline has been externally reviewed by experts prior to publication        |
|                                  | • A procedure for updating the guideline is provided                                |
| 4. Clarity of presentation       | • The recommendations are specific and unambiguous                                  |
|                                  | • The different options for management of the condition or health issue are clearly presented |
|                                  | • Key recommendations are easily identifiable                                      |
| 5. Applicability                 | • The guideline describes facilitators and barriers to its application             |
|                                  | • The guideline provides advice and/or tools on how the recommendations can be put into practice |
|                                  | • The potential resource implications of applying the recommendations have been considered |
|                                  | • The guideline presents monitoring and/or auditing criteria                         |
| 6. Editorial independence        | • The views of the funding body have not influenced the content of the guideline     |
|                                  | • Competing interests of guideline development group members have been recorded and addressed |

score–minimum possible score)/(maximum possible score–minimum possible), where the "obtained score" is the sum of the appraisers’ scores per each item. The AGREE-II instrument does not set a threshold of domain percentage score to differentiate quality. Instead, the manual leaves this cut-off at the discretion of the appraisers. To establish our threshold, a literature review of articles using the AGREE-II tool was performed. Reviews implementing this instrument established an arbitrary threshold of >70% to determine high-quality guidelines (51–53). As such, we used this published threshold to define high quality.

Finally, an overall assessment was attributed to each guideline. Although the AGREE-II instrument does not provide a specific rubric, it recommends that overall CPG quality assessment should be inferred from the domain scores, as well as the independent reviewers’ judgment. The overall assessment included an average score of the CPG, and whether the reviewers recommended, recommended with modifications, or did not recommend the CPG.

Risk of Bias Assessment
As per AGREE-II, the quality of CPGs is defined as “the confidence that the potential biases of guideline development have been addressed adequately and that the recommendations are both internally and externally valid and are feasible for practice.” The use of the AGREE-II tool allows appraisers to evaluate bias in the editorial independence and the rigor of development of published CPGs.

Mapping of Recommendations
Two reviewers (SG and ZR) extracted each CPG’s recommendations regarding the approach to initiating dupilumab in the treatment algorithms. Different approaches were identified, and guidelines were categorized based on the recommended sequence of the initiation of dupilumab. Approaches were categorized as rapid, conservative, and a slow sequential approach, based on the steps recommended prior to the introduction of dupilumab. A rapid sequential approach (1) was defined as initiation of dupilumab as second-line treatment after topicals. This classification was further subdivided as 1A: dupilumab is equivalent to antitumorinite/conventional systemic therapies, 1B: dupilumab is preferred over antitumorinite/conventional systemic therapies or narrow-band UVB phototherapy (nbUVB), and 1C: dupilumab is an equivalent choice to nbUVB. A conservative sequential approach (2) places dupilumab as the second-line treatment after the failure of topicals as well as an alternative, second-line therapeutic modality; in 2A, nbUVB is second and in 2B, antitumorinite/conventional systemic therapies are second. Finally, a slow sequential approach places dupilumab as 4th line, after the failure of topicals and 2nd line (nbUVB) and 3rd line modalities (antitumorinite/conventional systemic therapies).

RESULTS
Guideline Selection and Characteristics
The search yielded 424 articles on MEDLINE, 901 on EMBASE, 120 on CINAHL, and 639 on SCOPUS, with a total of 1,010 articles to be screened after removing duplicates (Figure 1). After abstract screening, 985 articles were excluded, with the remaining 25 articles assessed in full text. A total of 12 CPGs were retrieved (Figure 1; Table 2).

AGREE-II Scores
Scope and Purpose
The median score for scope and purpose domain items, including specific description of the CPG objectives, health question, and target population, was 78% (range 50–96%). Damiani et al. (35)
| References | Country                  | Severity of AD | Scoring tools used to assess AD severity | Consensus method |
|------------|--------------------------|----------------|-----------------------------------------|------------------|
|            |                          |                | Objective tools (CRO) Subjective tools (PRO) |                  |
| Ariens et al. (30) | European countries       | Severe         | BSA > 10                                | Delphi           |
| Boguniewicz et al. (31) | USA                      | Moderate–Severe| Individual lesions with moderate-severe features | n/s              |
| Boguniewicz et al. (32) | USA                      | Moderate–Severe| BSA > 10                                | n/s              |
| Brar et al. (33) | USA                      | Severe          | Individual lesions with severe features  | Delphi           |
| Calzavara et al. (34) | Italy                    | Moderate–Severe| EASI                                      | HRQoL > 10       |
| Damiani et al. (35) | Italy                    | Severe          | EASI 23–72                               | Delphi           |
| Lopes et al. (36) | Portugal                 | Severe          | SCORAD > 50                              | n/a              |
| Lynde et al. (37) | Canada                   | Moderate–Severe| BSA > 10                                | Committee        |
| Nowicki et al. (42) | Poland                   | Moderate–Severe| PGA > 3                                 | n/s              |
| Smith et al. (38) | Australia                | Moderate–Severe| BSA > 10                                | Delphi           |
| Thyssen et al. (39) | Nordic countries         | Moderate–Severe| EASI                                      | DLQI > 10        |
| Wollenberg et al. (40, 41) | European countries       | Moderate–Severe| SCORAD 25–50                             | n/a              |

*EASI and SCORAD were used as monitoring tools for treatment effect.

**Moderate-severe AD was defined as EASI > 16 or EASI < 16 with at least 1 of the 4 following conditions: localized to face, hands, genitals, itch with NRS < 7, DLQI > 10, sleep disturbance with NRS > 7.

*Unique in that it combines 2 subjective questions (itch and impact on sleep).

*Did not specify numerical scores.

BSA, body surface area; Committee, a committee or panel of experts discussed specific topics, reviewed the literature, and created recommendations based on expertise; CRO, clinician-reported outcome; Delphi, a Delphi or modified Delphi approach was used to reach consensus; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; HRQoL, Health Related Quality of Life; n/a, not applicable; n/s, not specified; NRS, pruritus Numerical Rating Scale; PGA, Patient Global Assessment; POEM, Patient-Oriented Eczema Measure; PRO, patient-reported outcome; SCORAD, SCORing Atopic Dermatitis.

and Nowicki et al. (42) did not meet the 70% threshold due to gaps in describing their target population.

**Stakeholder Involvement**

The median score for stakeholder involvement items (diverse stakeholders involved, patient perspectives sought, target guideline users defined) was 54% (range 28–85%). The only CPGs to obtain AGREE-II scores above 70% were Smith et al. (38) and Wollenberg et al. (40). The patients’ point of view and preferences were only taken into account in the Wollenberg et al. (40) and Lopes et al. (36) CPGs.

**Rigor of Development**

In this domain, the AGREE-II instrument items are extensive and detailed. They include the use of external experts’ review, the use of systematic methods, description of criteria used for evidence selection, disclosure of strengths and limitations, documentation of methods for formulating recommendations, and reference to explicit links to guidance with supporting evidence. Additional items include considerations of health benefits, side effects and risks, and a procedure for updating CPGs. No guideline met the above criteria with a score >70%. The median score of CPGs was 39% (range 21–63%). While most guidelines included health benefits, side effects, and risks in their recommendations, only two guidelines (35, 40) provided a procedure for updating their recommendations. Calzavara et al. (34), Smith et al. (38), and Wollenberg et al. (40) had their guidelines externally reviewed. Thyssen et al. (39) was the only guideline to adequately describe systematic methods and criteria used to select evidence.

**Clarity of Presentation**

Unambiguous and specific recommendations, clear management options, and easily identifiable key recommendations are the three criteria included here; this was the highest-scoring domain with a median of 85% (range 69–100%). Nearly all CPGs scored >70%. The guidelines accurately outlined the different
TABLE 3 | Standardized scores for each domain using the AGREE-II instrument.

| References                  | Scope and purpose | Stakeholder involvement | Rigor of development | Clarity of presentation | Applicability | Editorial independence | Overall AGREE-II quality (%) | Overall AGREE-II quality (/7) |
|-----------------------------|-------------------|-------------------------|-----------------------|-------------------------|---------------|------------------------|-------------------------------|-----------------------------|
| Ariens et al. (18)          | 74                | 43                      | 26                    | 80                      | 51            | 92                     | 4                            | Recommended with modifications |
| Boguniewicz et al. (31)     | 83                | 67                      | 43                    | 85                      | 14            | 86                     | 4.6                           | Recommended with modifications |
| Boguniewicz et al. (32)     | 85                | 50                      | 36                    | 89                      | 22            | 67                     | 3.3                           | Recommended with modifications |
| Brar et al. (33)            | 83                | 44                      | 21                    | 96                      | 26            | 81                     | 3.3                           | Recommended with modifications |
| Calzavara et al. (34)       | 91                | 63                      | 37                    | 69                      | 18            | 42                     | 2.6                           | Recommended with modifications |
| Damiani et al. (35)         | 50                | 37                      | 47                    | 74                      | 6             | 47                     | 3.6                           | Recommended with modifications |
| Lopes et al. (36)           | 74                | 50                      | 26                    | 91                      | 40            | 97                     | 3.3                           | Recommended with modifications |
| Lynde et al. (37)           | 74                | 46                      | 31                    | 78                      | 19            | 72                     | 3.3                           | Recommended with modifications |
| Nowicki et al. (42)         | 52                | 28                      | 24                    | 78                      | 26            | 53                     | 4                             | Recommended with modifications |
| Smith et al. (38)           | 93                | 72                      | 56                    | 91                      | 36            | 100                    | 5.6                           | Recommended                  |
| Thyssen et al. (39)         | 83                | 65                      | 63                    | 85                      | 39            | 86                     | 5.6                           | Recommended                  |
| Wollenberg et al. (40)      | 96                | 85                      | 55                    | 100                     | 35            | 94                     | 5.6                           | Recommended                  |

Scores presented in this table are the means calculated from the scores of the three independent appraisers. Domain scores were rounded.

Treatments for AD, with key recommendations illustrated by flow charts and algorithms.

**Applicability**
The criteria in this domain focus on tools, facilitators, and barriers to the implementation of CPGs, as well as health resource implications and monitoring/auditing criteria. These criteria were the least well met in the CPGs reviewed, as reflected by a median score of 27% in this domain (range 6–51%). No guidelines were scored >70%. Implementation strategies that included tools or recommendations on how to carry out the guidelines in practice were missing. Only Ariens et al. (18) and Thyssen et al. (39) acknowledged the cost/resource implications of their recommendations.

**Editorial Independence**
The median score for editorial independence (independence from funding body or conflicts of interest) was 76% (range 42–100%). Most CPGs clearly stated and addressed the conflicts of interest of their group members; however, the influence of funding bodies on CPG development was not always clarified.

**Overall Assessment in Considering a Guideline for Recommendation**
The CPGs that were reviewed generally performed well (Table 3). However, few CPGs met AGREE-II criteria for stakeholder involvement in particular, and the majority of items required for top AGREE-II quality scoring in the rigor of development and applicability domains were missing. Based on the domain scores and on the three appraisers’ personal judgement, three CPGs were recommended without changes, and nine were recommended with modifications.

**Mapping CPGs’ Recommendations**
The approaches of CPGs to the sequence of initiation of dupilumab in the treatment of adult AD were highly variable (Table 4). No single approach appeared in more than three guidelines.

**DISCUSSION**
In this systematic review of international CPGs for adult AD since the approval of dupilumab, we applied the validated AGREE-II instrument to measure and compare methodological quality before addressing recommendations for the use of this targeted on-label therapeutic. We found 12 relevant publications for supporting clinical decisions in the adult AD population; however, according to the validated AGREE-II instrument and a preset 70% threshold for item completion, only three CPGs were recommendable without modifications (38–40). Interestingly, recommendations regarding dupilumab initiation relative to conventional systemic therapy (CST) were highly variable, demonstrating a lack of consensus.

Our analysis of quality domains as per the AGREE-II found that most international guidelines demonstrated high scores in the quality domains of scope and purpose, clarity, and editorial independence. In contrast, AGREE-II criteria...
TABLE 4 | Recommended time for initiation of dupilumab relative to other treatment modalities, after 1st-line measures and topicals.

| Guideline | Rapid sequential | Conservative sequential | Slow sequential | No consensus |
|-----------|------------------|--------------------------|-----------------|-------------|
| 2A        | 2B               | 2C                       | 3A              | 3B          | 4A          |

- Ariens et al. (18) x
- Boguniewicz et al. (31) x
- Boguniewicz et al. (32) x
- Brar et al. (33) x
- Calzavara et al. (34) x
- Damiani et al. (35) x
- Lopes et al. (36) x
- Lynde et al. (37) x
- Nowicki et al. (42) x
- Smith et al. (38) x
- Thyssen et al. (39) x
- Wollenberg et al. (40) x

2. Rapid sequential approach: Dupilumab 2nd (after topicals).
   - 2A: As an equivalent to antimetabolite/conventional systemic therapies.
   - 2B: preferred over antimetabolite/conventional systemic therapies or phototherapy.
   - 2C: As an equivalent choice to phototherapy.

3. Conservative sequential approach: Dupilumab as 3rd line, (after topicals + 2nd intervention).
   - 3A: 2nd = narrow band UVB (nbUVB) phototherapy.
   - 3B: 2nd = antimetabolite/conventional systemic therapies.

4. Slow sequential approach: dupilumab as 4th line [after topicals + 2nd (nbUVB) + 3rd (conventional systemic therapy)]
   - 4A: 2nd = nbUVB, 3rd = conventional antimetabolite/conventional systemic therapies or vice versa or one conventional to another prior to dupilumab.

In this review, a variety of approaches were identified regarding the place of dupilumab initiation in the treatment algorithm for adult AD. These approaches were categorized as rapid, conservative, or slow-sequential, depending on the position of dupilumab as 2nd, 3rd, or 4th line after general measures and topical therapies. Nearly, one-third of the CPGs recommend a rapid sequential approach, introducing dupilumab after topical therapy failure, with two of four CPGs considering this biologic equivalent to antimetabolite/conventional immunomodulators. A more conservative sequential approach was suggested by less than half of CPGs, placing dupilumab as 3rd line after nbUVB or after antimetabolites/conventional systemic therapies. A slow sequential approach was proposed by two CPGs who recommend dupilumab as the 4th line, following the use of phototherapy and conventional systemics. Interestingly, the three CPGs with the highest metrics for quality and recommendable without modification based on the AGREE-II instrument (38-40) also had divergent management approaches, although two of three suggested initiating the anti-IL-4R alpha monoclonal therapy as third-line, after NB-UVB or CST failure. Notably, Thyssen et al. did not reach a consensus with respect to the time of initiation of dupilumab. Given dupilumab’s known efficacy and safety, these results may reflect disease heterogeneity, variability in payer or regulatory landscapes, and physician preference and comfort. However, there is a clear need for real-world evidence and comparative studies to address the lack of consensus, in particular now that a march of newer therapies lies ahead. Our review found a crucial element omitted by the majority of CPGs pertained to limitations of access and cost-benefit implications. Although currently approved and available in over 60 countries, pharmacoeconomic barriers and the need for regulatory approval across nations may contribute to the observed discrepancies and heterogeneity in management approaches (44, 54, 55). The variability in the accessibility of phototherapy across nations is another factor that contributes to discrepancies observed across CPGs.

Lastly, in most CPGs, the definition of treatment failure in AD is either too broad or entirely absent. Ariens et al. define treatment failure as discontinuation of the agent due to side effects or ineffectiveness using an adequate dose; however, definitions such as this were not found in other CPGs. Thus, the lack of criteria to define non-response poses challenges in deciding to change management approaches. A standard definition of treatment failure in AD is an important area for future research (40).

LIMITATIONS

A limitation of this study is the fact that the search was conducted on general databases (MEDLINE, EMBASE, SCOPUS, and CINAHL) and did not include a search of systematic review registries (e.g., PROSPERO, the Joanna Briggs Institute database of systematic reviews) or the grey literature (e.g., government and organization websites). However, a search of “atopic dermatitis management guidelines” was performed...
on Google and did not yield additional results that were not included in our search. Another limitation pertains to the application of the AGREE-II instrument. The AGREE-II instruction manual does not set a threshold to differentiate high-quality and low-quality CPG. For this reason, it is up to the appraisers to subjectively decide on an acceptable threshold. A threshold of 70% of the items was selected for this review based on evidence precedent, as publications using AGREE-II instrument established this preset point. The overall quality and decision to classify CPGs as “recommendable,” “recommendable with modifications,” or “non-recommendable” is based in part on reviewers’ judgement, making this a relatively subjective assessment, and the recommendations are made within the lens of the quality instrument itself. Furthermore, the AGREE II tool does not provide its users with the relative importance for each of the 6 domains. Thus, the scores of an AGREE-II evaluation should be interpreted cautiously, and all existing algorithms and guidelines found in this review contribute meaningful and significant recommendations as aids to clinical practice. Certain AGREE-II items, such as a mechanism for keeping guidelines up-to-date, consideration of potential resource implications of applying the recommendations, or monitoring and/or auditing criteria, may be beyond the scope or budgetary limitations of many existing groups developing such guidelines and may or may not be considered relevant to many practicing dermatologists or clinicians referencing them.

REFERENCES

1. Leung DY, Guttmann-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. (2014) 134:769–79. doi: 10.1016/j.jaci.2014.08.008
2. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol. (2011) 131:67–74. doi: 10.1093/jid/2010.251
3. Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. (2013) 132:1337–47. doi: 10.1016/j.jaci.2013.07.008
4. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. (2009) 124:1251–58.e1223. doi: 10.1016/j.jaci.2009.10.009
5. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. (2013) 132:1132–8. doi: 10.1016/j.jaci.2013.08.031
6. Blaabjerg MS, Andersen KE, Bindslev-Jensen C, Mertz CG. Decrease in the rate of sensitization and clinical allergy to natural rubber latex. Contact Dermatitis. (2015) 73:21–8. doi: 10.1111/cod.12386
7. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Prim. (2018) 4:1. doi: 10.1038/s41572-018-0001-z
8. Eichenfeld LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. (2014) 70:338–51. doi: 10.1016/j.jaad.2013.10.010
9. Eichenfeld LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzengerber K, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. (2014) 71:116–32. doi: 10.1016/j.jaad.2014.03.023
10. Simpson EL, Bruin-Weller M, Flohr C, Arden-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. (2017) 77:623–33. doi: 10.1016/j.jaad.2017.06.042
11. Feldman SR, Cox LS, Strowd LC, Gerber RA, Faulkner S, Sierka D, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefits. (2019) 12:83–93
12. Drucker AM, Eyerich K, de Bruin-Weller MS, Thysen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. (2018) 178:768–75. doi: 10.1111/bjd.15928
13. Sidbury R, Davis DM, Cohen DE, Cordero KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. (2014) 71:327–49. doi: 10.1016/j.jaad.2014.03.030
14. Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. (2014) 71:1218–33. doi: 10.1016/j.jaad.2014.08.038
15. Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol. (2018) 178:406–14. doi: 10.1111/bjd.15905
16. Gooderham MJ, Hong HC, Eshghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. (2018) 78(3 Suppl 1):S28–s36. doi: 10.1016/j.jaad.2017.12.022
17. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Parisier D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised,
double-blinded, placebo-controlled, phase 3 trial. *Lancet.* (2017) 389:2287–303. doi: 10.1016/S0140-6736(17)31191-1

18. Ariens LFJ, van der Schaff J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BiDay registry. *Allergy.* (2020) 75:116–26. doi: 10.1111/all.14080

19. Deleuran M, Thaci D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. *J Am Acad Dermatol.* (2020) 82:377–88. doi: 10.1016/j.jaad.2019.07.074

20. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. *JAMA Dermatol.* (2020) 156:44–56. doi: 10.1001/jamadermatol.2019.3336

21. Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. *Br J Dermatol.* (2020) 182:85–96. doi: 10.1111/bjd.18476

22. Paller AS, Siegfried EC, Thaci D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol.* (2020) 83:1282–93. doi: 10.1016/j.jaad.2020.06.054

23. Barbarot S, Wollenberg A, Silverberg JII, Deleuran M, Pellacani G, Armario Hita JC, et al. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. *J Dermatolog Treat.* (2020) 2020:1–12. doi: 10.1080/09546634.2017.1505550

24. Silverberg JII, Simpson EL, Ardeleanu M, Thaci D, Barbarot S, Bagel J, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the investigator’s Global Assessment: a pooled analysis of data from two phase III trials. *Br J Dermatol.* (2019) 181:80–7. doi: 10.1111/bjd.17791

25. Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). *J Am Acad Dermatol.* (2016) 75:506–15. doi: 10.1016/j.jaad.2016.04.054

26. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med.* (2016) 375:2335–48. doi: 10.1056/NEJMoa1610020

27. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. *J Am Acad Dermatol.* (2016) 74:491–8. doi: 10.1016/j.jaad.2015.10.043

28. Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema (atopic dermatitis) in adults: an Australian management consensus. *Australas J Dermatol.* (2020) 61:23–32. doi: 10.1111/ajd.13124

29. Thyssen JP, Berents T, Bradley M, Deleuran M, Grimstad O, Korhonen L, et al. Clinical management of atopic dermatitis in adults: mapping of expert opinion in 4 Nordic countries using a modified delphi process. *Acta Derm Venereol.* (2020) 100:1000015. doi: 10.2340/00015555-3369

30. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol.* (2018) 32:657–82. doi: 10.1111/1468-3083.13748

31. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults: part II. *J Eur Acad Dermatol Venereol.* (2018) 32:850–78. doi: 10.1111/1468-3083.13749

32. Nowicki RJ, Trzezciak M, Kaczmarski M, Wilkowska A, Czarnecka-Operacz M, Kowalewski C, et al. Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine Part II Systematic treatment and new therapeutic methods. *Postepy Dermatol Alergol.* (2020) 37:129–34. doi: 10.5114/ada.2020.94829

33. Seegraber M, Strou J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. *Expert Rev Clin Pharmacol.* (2018) 11:467–74. doi: 10.1080/17512433.2018.1449642

34. FDA approves new eczema drug dupixent. (2017). Available online at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-eczema-drug-duvipertin

35. Dupixent - European Medicines Agency. (2017). Available online at: https://www.ema.europa.eu/en medicines/human/EPAR/dupixent (accessed March 12, 2021).

36. DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma - Nov 17, 2020. (2020). Available online at: http://sanoconfedcan.mediaroom.com 2020-11-17-DUPIXENT-R-dupilumab-injection-now-approved-by-Health-Canada-for-patients-with-severe-asthma (accessed March 12, 2021).

37. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A, Rayyan—a web and mobile app for systematic reviews. *Syst Rev.* (2016) 5:210. doi: 10.1186/s13643-016-0384-4

38. Dans AL,Dans LF. Appraising a tool for guideline appraisal (the AGREE II instrument). *Clin Epidemiol.* (2010) 63:1281–2. doi: 10.1016/j.jclinepi.2010.06.005

39. Brouwer MC, Kerkvliet K, Sipphoff K, Consortium ANS. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. *BMJ.* (2016) 352:i1152. doi: 10.1136/bmj.i1152

40. Brouwer MC, Kho ME, Brownman GP, Burgers JS, Cluzeau E, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMJ.* (2010) 182:8389–842. doi: 10.1503/cmaj.090449

41. Bravo-Balado A, Plata M, Trujillo CG, Caicedo JL, Serrano A, Ramos A, et al. Is the development of clinical practice guidelines for non-neurogenic overactive bladder trustworthy? A critical appraisal using the Appraisal of
Guidelines, Research and Evaluation (AGREE) II instrument. BJU Int. (2019) 123:921–2. doi: 10.1111/bju.14684

52. Radwan M, Akbari Sari A, Rashidian A, Takian A, Abou-Dagga S, Elsous A. Appraising the methodological quality of the clinical practice guideline for diabetes mellitus using the AGREE II instrument: a methodological evaluation. JRSM Open. (2017) 8:2054270416682673. doi: 10.1177/2054270416682673

53. Zhang J, Xu J, Zhang W, Jiang M, Liu J, Xu L, et al. Quality appraisal of guidelines on cancer-associated thrombosis using AGREE II instrument and analysis of current status of new oral anticoagulants. Clin Appl Thromb Hemost. (2019) 25:1076029619846562. doi: 10.1177/1076029619846562

54. Kuznik A, Bégo-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, et al. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. (2017) 7:493–505. doi: 10.1007/s13555-017-0201-6

55. Wu KK, Nguyen KB, Sandhu JK, Armstrong AW. Does location matter? Geographic variations in healthcare resource use for atopic dermatitis in the United States. J Dermatolog Treat. (2019) 2019:1–7. doi: 10.1080/09546634.2019.1656796

Conflict of Interest: CJ reports grants from Innovaderm Research, McGill University Department of Medicine, MITACS, Canadian Dermatology Foundation, and Eczema Society of Canada, as well as grants, involvement in clinical studies, and/or consultancy work for Sanofi, Eli Lilly, AbbVie, Novartis, Bausch, Pfizer, Amgen, Celgene, Janssen, Boehringer Ingelheim, Asana, Leo, and UCB.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ghazal, Ridha, D'Aguanno, Nassim, Quaiattini, Netchiporouk, Poulin, Kalia, Marcoux, Piguet and Jack. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.